نتائج البحث 141-150 من 5285 لعملية البحث عن Relapse
The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...
... relapsed and frontline CD123-positive AML, and antileukemia activity of ... Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory ...
... relapsed NSCLC. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma. Rochester, Minn ...
The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or Refractory Non-Hodgkin Lymphoma, (RR ...
... Relapsed or Refractory NHL. The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or ...
NL-201 in Patients With Relapsed or Refractory Cancer · Study of Breast Cancer Risk Assessment in Female Patients with Benign Breast Disease · Evaluating Markers ...
... Relapsed Or Refractory Chronic Lymphocytic Leukemia. Rochester, Minn. This study will assess the safety, tolerability, pharmaokinetics, and preliminary ...
AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL ... relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have ...
The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.
A Study to Evaluate Tazemetostat Combined with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma. Rochester, Minn ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.